Dacomitinib (PF299804)
| Price | $2 |
| Package | 1kg |
| Min. Order: | 1kg |
| Supply Ability: | 100kg |
| Update Time: | 2019-07-06 |
Product Details
| Product Name: Dacomitinib (PF299804) | CAS No.: 1110813-31-4 |
| Min. Order: 1kg | Purity: 99% |
| Supply Ability: 100kg | Release date: 2019/07/06 |
| Product NUmber: : WM.562 |
| Dacomitinib (PF299804) Basic information |
| Description Biological activity Clinical Study References |
| Product Name: | Dacomitinib (PF299804) |
| Synonyms: | Dacomitinib;PF-00299804-03;PF-00299804;DacoMitinib (PF-00299804);DacoMitinib,PF299804;DacoMitinib (PF299804,PF-00299804);DacoMitinib (PF299804, PF299);(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide Dacomitinib (PF299804, PF299) |
| CAS: | 1110813-31-4 |
| MF: | C24H25ClFN5O2 |
| MW: | 469.9390032 |
| EINECS: | -0 |
| Product Categories: | Anti-cancer&immunity;Inhibitors |
| Mol File: | 1110813-31-4.mol |
 |
|
| Dacomitinib (PF299804) Chemical Properties |
| density | 1.344 |
| CAS DataBase Reference | 1110813-31-4 |
| Safety Information |
| HS Code | 29335990 |
| MSDS Information |
| Dacomitinib (PF299804) Usage And Synthesis |
| Description | Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib. |
| Biological activity | Dacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2. Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer. |
| Clinical Study | Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing. Clinical evaluation of dacomitinib is ongoing in a number of clinical trials in patients with advanced NSCLC across lines of therapies and a range of histologies and molecular subtypes, such as EGFR and KRAS status. Additionally, there is an ongoing clinical trial evaluating dacomitinib in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). |
| References | Ellis, Peter M,, et al. "Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. " Lancet Oncology 15.12(2014):1379. Kalous, O, et al. "Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. " Molecular Cancer Therapeutics11.9(2012):1978. https://en.wikipedia.org/wiki/Dacomitinib |
| Uses | PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively. |
| Definition | ChEBI: A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin 1-yl)but-2-enoyl group. |
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates：
Pharmaceutical intermediates;
OLED intermediates;
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-08 | ||
| $32.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $60.00 |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2026-05-05 | |
|
VIP4Y
|
shandong perfect biotechnology co.ltd
|
2026-03-27 | ||
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2025-08-21 | |||
|
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 | |||
|
VIP3Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2025-04-02 | ||
|
Nanjing Fred Technology Co., Ltd
|
2024-11-26 | |||
| $50.00 |
Anhui Ruihan Technology Co., Ltd
|
2023-09-21 | ||
| $10.00 |
Hebei Linwo New Material Technology Co., LTD
|
2023-07-31 |
China- Since: 2014-12-17
- Address: Zhengzhou High tech Zone, Henan Province, China
INQUIRY
楊俊青
sales@coreychem.com
sales@coreychem.com